Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.45 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402770 | 0.83 | ERN1 (0.42) | ERN1PTGS2PTGS1TDP2L3MBTL1 | |
| SCHEMBL5402767 | 0.83 | ERN1 (0.42) | ERN1PTGS2PTGS1TDP2L3MBTL1 | |
| SCHEMBL4898033 | 0.81 | ERN1 (0.62) | ERN1PTGS2PTGS1TDP2L3MBTL1 | |
| SCHEMBL5150260 | 0.81 | ERN1 (0.54) | ERN1PTGS2PTGS1TDP2L3MBTL1 | |
| SCHEMBL4896846 | 0.78 | ESR2 (0.49) | ERN1CYP17A1 | |
| SCHEMBL22309433 | 0.76 | ERN1 (0.46) | ERN1PTGS2PTGS1L3MBTL1AR | |
| SCHEMBL4898660 | 0.75 | ALDH1A1 (0.50) | ERN1L3MBTL1 | |
| SCHEMBL1726758 | 0.74 | ALDH1A1 (0.46) | ERN1L3MBTL1 | |
| SCHEMBL26704263 | 0.73 | ERN1 (0.51) | ERN1 | |
| SCHEMBL3691088 | 0.72 | ERN1 (0.57) | ERN1PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | WYETH (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | WYETH (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | WYETH (US) | 2008-02-07 | — | — | US | disclosed |
| US-7279600-B2 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279600-B2 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279600-B2 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1808429-A2 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | Wyeth a Corporation of the State of Delaware (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1808429-A2 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | Wyeth a Corporation of the State of Delaware (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1620392-B1 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH CORP (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1620392-B1 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH CORP (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1620392-A2 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | Wyeth (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050020676-A1 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH | 2005-01-27 | — | — | US | disclosed |
| WO-2004099122-A2 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | ESR1, ESR2, ESRRB | ERN1 2045/4885PTGS2 1000/4885PTGS1 857/4885 |
| US-20050020676-A1 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | ESR1, ESR2, ESRRB | ERN1 2045/4885PTGS2 1000/4885PTGS1 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.